A Phase 2 interventional study of REGN2176-3 and Intravitreal Aflibercept Injection (IAI) in Neovascular Age-Related Macular Degeneration, sponsored by Regeneron Pharmaceuticals. Terminated at 84 sites in 2 countries. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2020-10-26.
Sponsored by Regeneron Pharmaceuticals · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 66 studies testing aflibercept in Macular Degeneration — 2 open to participants now, 5 under way, 2 of them phase 3. aflibercept · Macular Degeneration.
Among the 66 studies testing aflibercept in Macular Degeneration, this one is the 6th largest by enrollment, is one of 6 that started in 2015, is one of 7 in phase 2, and was the 33rd registered.
1,459 studies on the registry are indexed under Macular Degeneration; 236 are open to participants now.
Browse Macular Degeneration studies →2 of the 66 studies testing aflibercept in Macular Degeneration are open now, in 9 countries. Recruiting first, the newest first:
Amgen · Sites in United States, Czechia, Hungary and 6 more countries
Ages 50+
Tianjin Medical University Eye Hospital
Ages 50–85
By country, each count listing its studies:
aflibercept: first FDA approval 2011 (EYLEA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 165 Macular Degeneration studies recruiting now, 116 (70%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.
This study: 50 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
66 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 11 · Phase 3 19 · Phase 4 27
First in 2005; this study’s year is marked. 6 started in 2015.
This study's enrollment of 505 is above the median of 56 across 985 interventional studies indexed under Macular Degeneration.
Median enrollment 55 across the 66 interventional studies. Of the 48 that completed or were terminated, 28 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
31 of 66 have an industry lead sponsor. The 10 most frequent:
Regeneron Pharmaceuticals is the lead sponsor of 412 studies on the registry; 90 are open to participants now.
Of its 126 completed or terminated interventional studies of FDA-regulated products, 79 (63%) have results posted.
17 studies in Macular Degeneration by Regeneron Pharmaceuticals: 2 open now, 3 under way, 2 of them phase 3. Of 14 finished, 9 (64%) have results posted.
Among the 17 studies in Macular Degeneration by Regeneron Pharmaceuticals, this one is the 4th largest by enrollment of the 16 interventional ones that give a count, is the only one that started in 2015, is one of 5 in phase 2, and was the 10th registered.
Regeneron Pharmaceuticals’s Macular Degeneration studies by the year they started, since 2005.
2 of the studies testing aflibercept in Macular Degeneration that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07614776Phase 3AmgenA Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular Degeneration | 2027-07-31 |
| NCT04932980Berner AugenklinikComparison of Rapid Aflibercept and Brolucizumab T&E in wAMD | 2027-06 |
Add all 2 to your calendar (.ics) → With an account.
Among the 66 studies testing aflibercept in Macular Degeneration, from their registry updates:
Among Regeneron Pharmaceuticals’s 17 in Macular Degeneration:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective of the study was to explore the effect of REGN2176-3 on the Early Treatment Diabetic Retinopathy Scale (ETDRS) best-corrected visual acuity (BCVA) in participants with neovascular age-related macular degeneration (AMD), compared to intravitreal aflibercept injection (IAI) monotherapy.
The secondary objectives of the study were the following:
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Intravitreal injection of REGN2176-3 (REGN2176 1 mg and REGN3 2 mg) every 4 weeks for 12 weeks. After Week 12, dosing was monthly up to Week 28, then criteria based re-dosing from Week 28-52.
Drug: REGN2176-3
Intravitreal injection of REGN2176-3 (REGN2176 3 mg and REGN3 2 mg) every 4 weeks for 12 weeks. After Week 12, dosing was monthly up to Week 28, then criteria based re-dosing from Week 28-52.
Drug: REGN2176-3
IAI every 4 weeks for 12 weeks. After Week 12, dosing was monthly up to Week 28, then criteria based re-dosing from Week 28-52.
Drug: Intravitreal Aflibercept Injection (IAI)
Intravitreal injection of REGN2176-3 (REGN2176 3 mg and REGN3 2 mg) every 4 weeks for 12 weeks. After Week 12, dosing was monthly with IAI 2 mg up to Week 28, then criteria based re-dosing from Week 28-52.
Drug: Intravitreal Aflibercept Injection (IAI)
IAI every 4 weeks for 12 weeks. After Week 12, dosing was monthly with REGN2176-3 (REGN2176 3 mg and REGN3 2 mg) up to Week 28, then criteria based re-dosing from Week 28-52.
Drug: REGN2176-3
Also known as: Eylea®
Change From Baseline in Best Corrected Visual Acuity (BCVA) of the Study Eye at Week 12
Visual function of the study eye was assessed using the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol at 4 meters. BCVA score was measured using an eye chart and was reported as the number of letters read correctly at a testing distance of 4 meters using the ETDRS Scale (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly means that vision has improved. Change from baseline calculated by subtracting baseline value from observed post-baseline value at Week 12.
Time frame: Baseline, Week 12
Change From Baseline in Central Subfield Retinal Thickness (CST) at Week 12, as Measured by Optical Coherence Tomography (OCT)
CST was assessed using spectral domain optical coherence tomography (SD-OCT), a non-invasive diagnostic system providing high-resolution imaging sections of the retina. SD-OCT was performed in the study eye after pupil dilation. A negative change from baseline indicated improvement. Change from baseline calculated by subtracting baseline value from LOCF post-baseline value at Week 12.
Time frame: Baseline, Week 12
Percentage of Participants With Complete Resolution of Intraretinal and Subretinal Fluid From Baseline at Week 12 Measured by Optical Coherence Tomography (OCT)
CST was assessed using spectral domain optical coherence tomography (SD-OCT), a non-invasive diagnostic system providing high-resolution imaging sections of the retina. SD-OCT was performed in the study eye after pupil dilation.
Time frame: Week 12
Change From Baseline in Choroidal Neovascularization (CNV) Area at Week 12 Measured by Fluorescein Angiography (FA)
The anatomical state of the retinal vasculature of the study eye and the fellow eye was evaluated by funduscopic examination, fundus photography and FA to evaluate the total lesion area, CNV area, classic CNV area, and fluorescein leakage. CNV area values measured in square millimeters, each disc area was equivalent to 2.54 mm\^2 on the retina; lower values represent better outcomes.
Time frame: Baseline, Week 12
Change From Baseline in Total Lesion Size at Week 12 Measured by Fluorescein Angiography (FA)
Total Lesion Size was assessed by Fluorescein Angiography.
Time frame: Baseline, Week 12
Percentage of Participants Who Gained At Least 15 Letters in BCVA From Baseline at Week 12, Measured by 4-meter Early Treatment Diabetic Retinopathy Scale (ETDRS)
Visual function of the study eye was assessed using the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol at 4 meters. BCVA score was measured using an eye chart and was reported as the number of letters read correctly at a testing distance of 4 meters using the ETDRS Scale (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly means that vision has improved. This outcome assessed the percentage of participants who gained 15 or more letters of visual acuity at Week 12 compared with baseline.
Time frame: Week 12
Percent Change From Baseline in Subretinal Hyperreflectivity Material (SHM) at Week 12 Measured by Optical Coherence Tomography (OCT)
SHM was assessed using spectral domain optical coherence tomography (SD-OCT), a non-invasive diagnostic system providing high-resolution imaging sections of the retina. SD-OCT was performed in the study eye after pupil dilation. A negative change from baseline indicated improvement.
Time frame: Baseline, Week 12
Change From Baseline in Central Retinal/Lesion Thickness at Week 12 Measured by Optical Coherence Tomography (OCT)
CST was assessed using spectral domain optical coherence tomography (SD-OCT), a non-invasive diagnostic system providing high-resolution imaging sections of the retina. SD-OCT was performed in the study eye after pupil dilation. A negative change from baseline indicated improvement. Change from baseline calculated by subtracting baseline value from LOCF post-baseline value at Week 12.
Time frame: Baseline, Week 12
The study was conducted at 82 sites in US and 11 sites in Japan. A total of 804 participants were screened. Out of 804 participants, 505 were randomized and treated.
| Milestone | Group 1: REGN2176-3 (1 mg:2 mg) | Group 2: REGN2176-3 (3 mg:2 mg) | Group 3: Intravitreal Aflibercept Injection (IAI) 2 mg | Group 4: REGN2176-3 (3 mg:2 mg) to IAI 2 mg | Group 5: IAI 2 mg to REGN2176-3 (3 mg:2 mg) |
|---|---|---|---|---|---|
| Started | 103 | 200 | 202 | 0 | 0 |
| Completed | 101 | 196 | 200 | 0 | 0 |
| Not completed | 2 | 4 | 2 | 0 | 0 |
| Withdrew: Adverse event | 0 | 2 | 0 | 0 | 0 |
| Withdrew: Death | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Physician decision | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 2 | 1 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 | 0 | 0 |
| Milestone | Group 1: REGN2176-3 (1 mg:2 mg) | Group 2: REGN2176-3 (3 mg:2 mg) | Group 3: Intravitreal Aflibercept Injection (IAI) 2 mg | Group 4: REGN2176-3 (3 mg:2 mg) to IAI 2 mg | Group 5: IAI 2 mg to REGN2176-3 (3 mg:2 mg) |
|---|---|---|---|---|---|
| Started | 103 | 106 | 108 | 94 | 94 |
| Completed | 70 | 64 | 71 | 67 | 67 |
| Not completed | 33 | 42 | 37 | 27 | 27 |
| Withdrew: Adverse event | 3 | 7 | 6 | 2 | 2 |
| Withdrew: Death | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Physician decision | 26 | 28 | 26 | 21 | 24 |
| Withdrew: Withdrawal by subject | 3 | 4 | 4 | 1 | 0 |
| Withdrew: Lost to follow-up | 0 | 2 | 1 | 2 | 1 |
| Withdrew: Other un-specified | 0 | 1 | 0 | 1 | 0 |
Visual function of the study eye was assessed using the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol at 4 meters. BCVA score was measured using an eye chart and was reported as the number of letters read correctly at a testing distance of 4 meters using the ETDRS Scale (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly means that vision has improved. Change from baseline calculated by subtracting baseline value from observed post-baseline value at Week 12.
| Letters | Group 1: REGN2176-3 (1 mg:2 mg) | Group 2: REGN2176-3 (3 mg:2 mg) | Group 3: Intravitreal Aflibercept Injection (IAI) 2 mg |
|---|---|---|---|
| Change From Baseline in Best Corrected Visual Acuity (BCVA) of the Study Eye at Week 12 | 5.9 ± 1.01 | 5.7 ± 0.73 | 7.4 ± 0.72 |
CST was assessed using spectral domain optical coherence tomography (SD-OCT), a non-invasive diagnostic system providing high-resolution imaging sections of the retina. SD-OCT was performed in the study eye after pupil dilation. A negative change from baseline indicated improvement. Change from baseline calculated by subtracting baseline value from LOCF post-baseline value at Week 12.
| Microns | Group 1: REGN2176-3 (1 mg:2 mg) | Group 2: REGN2176-3 (3 mg:2 mg) | Group 3: Intravitreal Aflibercept Injection (IAI) 2 mg |
|---|---|---|---|
| Change From Baseline in Central Subfield Retinal Thickness (CST) at Week 12, as Measured by Optical Coherence Tomography (OCT) | -131.1 ± 6.88 | -116.9 ± 4.96 | -134.4 ± 4.92 |
CST was assessed using spectral domain optical coherence tomography (SD-OCT), a non-invasive diagnostic system providing high-resolution imaging sections of the retina. SD-OCT was performed in the study eye after pupil dilation.
| Percentage of Participants | Group 1: REGN2176-3 (1 mg:2 mg) | Group 2: REGN2176-3 (3 mg:2 mg) | Group 3: Intravitreal Aflibercept Injection (IAI) 2 mg |
|---|---|---|---|
| Percentage of Participants With Complete Resolution of Intraretinal and Subretinal Fluid From Baseline at Week 12 Measured by Optical Coherence Tomography (OCT) | 35.0 | 24.0 | 42.1 |
The anatomical state of the retinal vasculature of the study eye and the fellow eye was evaluated by funduscopic examination, fundus photography and FA to evaluate the total lesion area, CNV area, classic CNV area, and fluorescein leakage. CNV area values measured in square millimeters, each disc area was equivalent to 2.54 mm\^2 on the retina; lower values represent better outcomes.
| Square Millimeter (mm^2) | Group 1: REGN2176-3 (1 mg:2 mg) | Group 2: REGN2176-3 (3 mg:2 mg) | Group 3: Intravitreal Aflibercept Injection (IAI) 2 mg |
|---|---|---|---|
| Change From Baseline in Choroidal Neovascularization (CNV) Area at Week 12 Measured by Fluorescein Angiography (FA) | -3.4 ± 0.44 | -2.0 ± 0.31 | -3.6 ± 0.31 |
Total Lesion Size was assessed by Fluorescein Angiography.
| mm | Group 1: REGN2176-3 (1 mg:2 mg) | Group 2: REGN2176-3 (3 mg:2 mg) | Group 3: Intravitreal Aflibercept Injection (IAI) 2 mg |
|---|---|---|---|
| Change From Baseline in Total Lesion Size at Week 12 Measured by Fluorescein Angiography (FA) | -3.1 ± 0.43 | -2.1 ± 0.31 | -3.5 ± 0.31 |
Visual function of the study eye was assessed using the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol at 4 meters. BCVA score was measured using an eye chart and was reported as the number of letters read correctly at a testing distance of 4 meters using the ETDRS Scale (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly means that vision has improved. This outcome assessed the percentage of participants who gained 15 or more letters of visual acuity at Week 12 compared with baseline.
| Percentage of Participants | Group 1: REGN2176-3 (1 mg:2 mg) | Group 2: REGN2176-3 (3 mg:2 mg) | Group 3: Intravitreal Aflibercept Injection (IAI) 2 mg |
|---|---|---|---|
| Percentage of Participants Who Gained At Least 15 Letters in BCVA From Baseline at Week 12, Measured by 4-meter Early Treatment Diabetic Retinopathy Scale (ETDRS) | 11.7 | 18.5 | 21.8 |
SHM was assessed using spectral domain optical coherence tomography (SD-OCT), a non-invasive diagnostic system providing high-resolution imaging sections of the retina. SD-OCT was performed in the study eye after pupil dilation. A negative change from baseline indicated improvement.
| Percent change | Group 1: REGN2176-3 (1 mg:2 mg) | Group 2: REGN2176-3 (3 mg:2 mg) | Group 3: Intravitreal Aflibercept Injection (IAI) 2 mg |
|---|---|---|---|
| Percent Change From Baseline in Subretinal Hyperreflectivity Material (SHM) at Week 12 Measured by Optical Coherence Tomography (OCT) | -50.0 ± 5.94 | -41.9 ± 4.17 | -48.8 ± 4.14 |
CST was assessed using spectral domain optical coherence tomography (SD-OCT), a non-invasive diagnostic system providing high-resolution imaging sections of the retina. SD-OCT was performed in the study eye after pupil dilation. A negative change from baseline indicated improvement. Change from baseline calculated by subtracting baseline value from LOCF post-baseline value at Week 12.
| Microns | Group 1: REGN2176-3 (1 mg:2 mg) | Group 2: REGN2176-3 (3 mg:2 mg) | Group 3: Intravitreal Aflibercept Injection (IAI) 2 mg |
|---|---|---|---|
| Change From Baseline in Central Retinal/Lesion Thickness at Week 12 Measured by Optical Coherence Tomography (OCT) | -150.7 ± 7.40 | -139.6 ± 5.32 | -160.4 ± 5.29 |
Collected over All Adverse Events (AEs) were collected from signature of the informed consent form up to the final visit (Week 52) regardless of seriousness or relationship to investigational product.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Group 1: REGN2176-3 (1 mg:2 mg) | 3/103 (2.9%) | 17/103 (16.5%) | 48/103 (46.6%) |
| Group 2: REGN2176-3 (3 mg:2 mg) | 2/106 (1.9%) | 20/106 (18.9%) | 50/106 (47.2%) |
| Group 3: Intravitreal Aflibercept Injection (IAI) 2 mg | 3/108 (2.8%) | 23/108 (21.3%) | 51/108 (47.2%) |
| Group 4: REGN2176-3 (3 mg:2 mg) to IAI 2 mg | 1/94 (1.1%) | 17/94 (18.1%) | 52/94 (55.3%) |
| Group 5: IAI 2 mg to REGN2176-3 (3 mg:2 mg) | 1/94 (1.1%) | 15/94 (16%) | 52/94 (55.3%) |
| Event | Group 1: REGN2176-3 (1 mg:2 mg) | Group 2: REGN2176-3 (3 mg:2 mg) | Group 3: Intravitreal Aflibercept Injection (IAI) 2 mg | Group 4: REGN2176-3 (3 mg:2 mg) to IAI 2 mg | Group 5: IAI 2 mg to REGN2176-3 (3 mg:2 mg) |
|---|---|---|---|---|---|
| Atrial fibrillationCardiac disorders | 1/103 | 1/106 | 0/108 | 4/94 | 1/94 |
| PneumoniaInfections and infestations | 1/103 | 1/106 | 0/108 | 3/94 | 1/94 |
| FallInjury, poisoning and procedural complications | 0/103 | 2/106 | 1/108 | 3/94 | 1/94 |
| Cardiac failure congestiveCardiac disorders | 3/103 | 0/106 | 0/108 | 1/94 | 0/94 |
| Retinal haemorrhageEye disorders | 0/103 | 0/106 | 0/108 | 0/94 | 2/94 |
| Visual acuity reducedEye disorders | 2/103 | 1/106 | 0/108 | 0/94 | 1/94 |
| UveitisEye disorders | 1/103 | 2/106 | 0/108 | 1/94 | 0/94 |
| SepsisInfections and infestations | 0/103 | 2/106 | 0/108 | 1/94 | 1/94 |
| Femur fractureInjury, poisoning and procedural complications | 0/103 | 2/106 | 0/108 | 0/94 | 1/94 |
| BronchitisInfections and infestations | 0/103 | 0/106 | 2/108 | 0/94 | 0/94 |
| Event | Group 1: REGN2176-3 (1 mg:2 mg) | Group 2: REGN2176-3 (3 mg:2 mg) | Group 3: Intravitreal Aflibercept Injection (IAI) 2 mg | Group 4: REGN2176-3 (3 mg:2 mg) to IAI 2 mg | Group 5: IAI 2 mg to REGN2176-3 (3 mg:2 mg) |
|---|---|---|---|---|---|
| Urinary tract infectionInfections and infestations | 7/103 | 7/106 | 4/108 | 7/94 | 13/94 |
| Conjunctival haemorrhageEye disorders | 6/103 | 4/106 | 6/108 | 11/94 | 9/94 |
| Vitreous floatersEye disorders | 2/103 | 1/106 | 1/108 | 3/94 | 10/94 |
| Neovascular age-related macular degenerationEye disorders | 1/103 | 10/106 | 8/108 | 8/94 | 5/94 |
| HypertensionVascular disorders | 6/103 | 4/106 | 10/108 | 2/94 | 5/94 |
| NasopharyngitisInfections and infestations | 3/103 | 6/106 | 9/108 | 5/94 | 8/94 |
| Retinal haemorrhageEye disorders | 6/103 | 8/106 | 3/108 | 5/94 | 3/94 |
| Vitreous detachmentEye disorders | 3/103 | 3/106 | 2/108 | 7/94 | 3/94 |
| SinusitisInfections and infestations | 2/103 | 7/106 | 2/108 | 4/94 | 7/94 |
| Eye painEye disorders | 3/103 | 5/106 | 1/108 | 6/94 | 2/94 |
Baseline population included all randomized participants.
| Age, Continuous(years) | Group 1: REGN2176-3 (1 mg:2 mg) | Group 2: REGN2176-3 (3 mg:2 mg) | Group 3: Intravitreal Aflibercept Injection (IAI) 2 mg | Total |
|---|---|---|---|---|
| Mean | 79.2 ± 8.01 | 78.6 ± 8.77 | 77.7 ± 8.61 | 78.3 ± 8.56 |
| Sex: Female, Male(Participants) | Group 1: REGN2176-3 (1 mg:2 mg) | Group 2: REGN2176-3 (3 mg:2 mg) | Group 3: Intravitreal Aflibercept Injection (IAI) 2 mg | Total |
|---|---|---|---|---|
| Female | 61 | 121 | 135 | 317 |
| Male | 42 | 79 | 67 | 188 |
| Ethnicity (NIH/OMB)(Participants) | Group 1: REGN2176-3 (1 mg:2 mg) | Group 2: REGN2176-3 (3 mg:2 mg) | Group 3: Intravitreal Aflibercept Injection (IAI) 2 mg | Total |
|---|---|---|---|---|
| Hispanic or Latino | 1 | 7 | 6 | 14 |
| Not Hispanic or Latino | 102 | 193 | 196 | 491 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Group 1: REGN2176-3 (1 mg:2 mg) | Group 2: REGN2176-3 (3 mg:2 mg) | Group 3: Intravitreal Aflibercept Injection (IAI) 2 mg | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 1 | 1 |
| Asian | 5 | 9 | 10 | 24 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 1 | 2 | 3 |
| White | 98 | 189 | 186 | 473 |
| More than one race | 0 | 1 | 1 | 2 |
| Unknown or Not Reported | 0 | 0 | 2 | 2 |
| Region of Enrollment(Participants) | Group 1: REGN2176-3 (1 mg:2 mg) | Group 2: REGN2176-3 (3 mg:2 mg) | Group 3: Intravitreal Aflibercept Injection (IAI) 2 mg | Total |
|---|---|---|---|---|
| United States | 98 | 193 | 194 | 485 |
| Japan | 5 | 7 | 8 | 20 |
Ran from May 2015 to primary completion in Aug 2016, 15 months.
Results were first posted in Oct 2020, 4 years 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Aflibercept